Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Research Report 2026(Status and Outlook)
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.The Glucagon-like peptide 1 (GLP-1) market is driven by the increasing prevalence of diabetes and the growing demand for effective and innovative diabetes treatments. GLP-1 is a hormone that plays a crucial role in regulating blood sugar levels and is used in the treatment of type 2 diabetes. The rise in the number of diabetic patients and the need for better glycemic control contribute to market growth as GLP-1-based therapies offer significant benefits, including glucose-lowering effects and weight management. Moreover, advancements in GLP-1 analog formulations, such as long-acting and once-weekly options, have improved patient compliance and treatment outcomes. However, the market also faces challenges, including the cost of GLP-1 treatments and the need for further research to optimize dosing and combination therapies. Additionally, addressing the barriers to GLP-1 adoption, such as injection-related fears, can pose obstacles for broader market penetration. To succeed, companies must focus on research and development to offer innovative and cost-effective GLP-1 therapies, collaborate with healthcare providers to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated diabetes treatments based on GLP-1.
The global Glucagon-like peptide 1 (GLP-1)-based Therapies market size was estimated at USD 5931.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 4.30% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Glucagon-like peptide 1 (GLP-1)-based Therapies market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Glucagon-like peptide 1 (GLP-1)-based Therapies market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Glucagon-like peptide 1 (GLP-1)-based Therapies market.
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Abbott Laboratories
Market Segmentation (by Type)
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Market Segmentation (by Application)
Hospital
Pharmacy
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Glucagon-like peptide 1 (GLP-1)-based Therapies Market
Overview of the regional outlook of the Glucagon-like peptide 1 (GLP-1)-based Therapies Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Glucagon-like peptide 1 (GLP-1)-based Therapies Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Glucagon-like peptide 1 (GLP-1)-based Therapies, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Glucagon-like peptide 1 (GLP-1)-based Therapies market size was estimated at USD 5931.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 4.30% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Glucagon-like peptide 1 (GLP-1)-based Therapies market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Glucagon-like peptide 1 (GLP-1)-based Therapies market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Glucagon-like peptide 1 (GLP-1)-based Therapies market.
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Abbott Laboratories
Market Segmentation (by Type)
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Market Segmentation (by Application)
Hospital
Pharmacy
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Glucagon-like peptide 1 (GLP-1)-based Therapies Market
Overview of the regional outlook of the Glucagon-like peptide 1 (GLP-1)-based Therapies Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Glucagon-like peptide 1 (GLP-1)-based Therapies Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Glucagon-like peptide 1 (GLP-1)-based Therapies, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Glucagon-like peptide 1 (GLP-1)-based Therapies
1.2 Key Market Segments
1.2.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Type
1.2.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Product Life Cycle
3.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Manufacturers (2020-2025)
3.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Manufacturers (2020-2025)
3.5 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competitive Situation and Trends
3.8.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Concentration Rate
3.8.2 Global 5 and 10 Largest Glucagon-like peptide 1 (GLP-1)-based Therapies Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES INDUSTRY CHAIN ANALYSIS
4.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Glucagon-like peptide 1 (GLP-1)-based Therapies Market
5.7 ESG Ratings of Leading Companies
6 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2020-2025)
6.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Type (2020-2025)
6.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Type (2020-2025)
7 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Sales by Application (2020-2025)
7.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) by Application (2020-2025)
7.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate by Application (2020-2025)
8 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET SALES BY REGION
8.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region
8.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region
8.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region
8.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region
8.3 North America
8.3.1 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.3.2 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.4.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.5.2 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.6.2 South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.7.2 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET PRODUCTION BY REGION
9.1 Global Production of Glucagon-like peptide 1 (GLP-1)-based Therapies by Region(2020-2025)
9.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2020-2025)
9.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production
9.4.1 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production Growth Rate (2020-2025)
9.4.2 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production
9.5.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production Growth Rate (2020-2025)
9.5.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2020-2025)
9.6.1 Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production Growth Rate (2020-2025)
9.6.2 Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2020-2025)
9.7.1 China Glucagon-like peptide 1 (GLP-1)-based Therapies Production Growth Rate (2020-2025)
9.7.2 China Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Novo Nordisk
10.1.1 Novo Nordisk Basic Information
10.1.2 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.1.3 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.1.4 Novo Nordisk Business Overview
10.1.5 Novo Nordisk SWOT Analysis
10.1.6 Novo Nordisk Recent Developments
10.2 AstraZeneca
10.2.1 AstraZeneca Basic Information
10.2.2 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.2.3 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.2.4 AstraZeneca Business Overview
10.2.5 AstraZeneca SWOT Analysis
10.2.6 AstraZeneca Recent Developments
10.3 Eli Lily
10.3.1 Eli Lily Basic Information
10.3.2 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.3.3 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.3.4 Eli Lily Business Overview
10.3.5 Eli Lily SWOT Analysis
10.3.6 Eli Lily Recent Developments
10.4 GSK
10.4.1 GSK Basic Information
10.4.2 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.4.3 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.4.4 GSK Business Overview
10.4.5 GSK Recent Developments
10.5 Sanofi
10.5.1 Sanofi Basic Information
10.5.2 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.5.3 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.5.4 Sanofi Business Overview
10.5.5 Sanofi Recent Developments
10.6 Bristol-Myers Squibb
10.6.1 Bristol-Myers Squibb Basic Information
10.6.2 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.6.3 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.6.4 Bristol-Myers Squibb Business Overview
10.6.5 Bristol-Myers Squibb Recent Developments
10.7 Abbott Laboratories
10.7.1 Abbott Laboratories Basic Information
10.7.2 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.7.3 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.7.4 Abbott Laboratories Business Overview
10.7.5 Abbott Laboratories Recent Developments
11 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET FORECAST BY REGION
11.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast
11.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country
11.2.3 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region
11.2.4 South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Glucagon-like peptide 1 (GLP-1)-based Therapies by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2026-2035)
12.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2026-2035)
12.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Application (2026-2035)
12.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) Forecast by Application
12.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Glucagon-like peptide 1 (GLP-1)-based Therapies
1.2 Key Market Segments
1.2.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Type
1.2.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Product Life Cycle
3.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Manufacturers (2020-2025)
3.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Manufacturers (2020-2025)
3.5 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Competitive Situation and Trends
3.8.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Concentration Rate
3.8.2 Global 5 and 10 Largest Glucagon-like peptide 1 (GLP-1)-based Therapies Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES INDUSTRY CHAIN ANALYSIS
4.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Glucagon-like peptide 1 (GLP-1)-based Therapies Market
5.7 ESG Ratings of Leading Companies
6 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2020-2025)
6.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Type (2020-2025)
6.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Type (2020-2025)
7 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Sales by Application (2020-2025)
7.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) by Application (2020-2025)
7.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate by Application (2020-2025)
8 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET SALES BY REGION
8.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region
8.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region
8.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region
8.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region
8.3 North America
8.3.1 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.3.2 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.4.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.5.2 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country
8.6.2 South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
8.7.2 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET PRODUCTION BY REGION
9.1 Global Production of Glucagon-like peptide 1 (GLP-1)-based Therapies by Region(2020-2025)
9.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2020-2025)
9.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production
9.4.1 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production Growth Rate (2020-2025)
9.4.2 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production
9.5.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production Growth Rate (2020-2025)
9.5.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2020-2025)
9.6.1 Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production Growth Rate (2020-2025)
9.6.2 Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2020-2025)
9.7.1 China Glucagon-like peptide 1 (GLP-1)-based Therapies Production Growth Rate (2020-2025)
9.7.2 China Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Novo Nordisk
10.1.1 Novo Nordisk Basic Information
10.1.2 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.1.3 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.1.4 Novo Nordisk Business Overview
10.1.5 Novo Nordisk SWOT Analysis
10.1.6 Novo Nordisk Recent Developments
10.2 AstraZeneca
10.2.1 AstraZeneca Basic Information
10.2.2 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.2.3 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.2.4 AstraZeneca Business Overview
10.2.5 AstraZeneca SWOT Analysis
10.2.6 AstraZeneca Recent Developments
10.3 Eli Lily
10.3.1 Eli Lily Basic Information
10.3.2 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.3.3 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.3.4 Eli Lily Business Overview
10.3.5 Eli Lily SWOT Analysis
10.3.6 Eli Lily Recent Developments
10.4 GSK
10.4.1 GSK Basic Information
10.4.2 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.4.3 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.4.4 GSK Business Overview
10.4.5 GSK Recent Developments
10.5 Sanofi
10.5.1 Sanofi Basic Information
10.5.2 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.5.3 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.5.4 Sanofi Business Overview
10.5.5 Sanofi Recent Developments
10.6 Bristol-Myers Squibb
10.6.1 Bristol-Myers Squibb Basic Information
10.6.2 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.6.3 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.6.4 Bristol-Myers Squibb Business Overview
10.6.5 Bristol-Myers Squibb Recent Developments
10.7 Abbott Laboratories
10.7.1 Abbott Laboratories Basic Information
10.7.2 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
10.7.3 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Market Performance
10.7.4 Abbott Laboratories Business Overview
10.7.5 Abbott Laboratories Recent Developments
11 GLUCAGON-LIKE PEPTIDE 1 (GLP-1)-BASED THERAPIES MARKET FORECAST BY REGION
11.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast
11.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country
11.2.3 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region
11.2.4 South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Glucagon-like peptide 1 (GLP-1)-based Therapies by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2026-2035)
12.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2026-2035)
12.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Forecast by Application (2026-2035)
12.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) Forecast by Application
12.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Type (M USD)
Table 4. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Application
Table 5. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Comparison by Region (M USD)
Table 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon-like peptide 1 (GLP-1)-based Therapies as of 2025)
Table 11. Global Market Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (K MT)
Table 27. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Type (M USD)
Table 28. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) by Type (2020-2025)
Table 29. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2020-2025)
Table 30. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) by Type (2020-2025)
Table 31. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Type (2020-2025)
Table 32. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (USD/KG) by Type (2020-2025)
Table 33. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) by Application
Table 34. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Application
Table 35. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2020-2025) & (K MT)
Table 36. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2020-2025)
Table 37. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Application (2020-2025) & (M USD)
Table 38. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application (2020-2025)
Table 39. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate by Application (2020-2025)
Table 40. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2020-2025) & (K MT)
Table 41. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2020-2025)
Table 42. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region (2020-2025) & (M USD)
Table 43. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region (2020-2025)
Table 44. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2020-2025) & (K MT)
Table 45. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2020-2025) & (K MT)
Table 47. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region (2020-2025) & (M USD)
Table 50. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2020-2025) & (K MT)
Table 51. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region (2020-2025) & (M USD)
Table 54. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT) by Region(2020-2025)
Table 55. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2020-2025)
Table 57. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Novo Nordisk Basic Information
Table 63. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 64. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Novo Nordisk Business Overview
Table 66. Novo Nordisk SWOT Analysis
Table 67. Novo Nordisk Recent Developments
Table 68. AstraZeneca Basic Information
Table 69. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 70. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. AstraZeneca Business Overview
Table 72. AstraZeneca SWOT Analysis
Table 73. AstraZeneca Recent Developments
Table 74. Eli Lily Basic Information
Table 75. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 76. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Eli Lily Business Overview
Table 78. Eli Lily SWOT Analysis
Table 79. Eli Lily Recent Developments
Table 80. GSK Basic Information
Table 81. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 82. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. GSK Business Overview
Table 84. GSK Recent Developments
Table 85. Sanofi Basic Information
Table 86. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 87. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Sanofi Business Overview
Table 89. Sanofi Recent Developments
Table 90. Bristol-Myers Squibb Basic Information
Table 91. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 92. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Bristol-Myers Squibb Business Overview
Table 94. Bristol-Myers Squibb Recent Developments
Table 95. Abbott Laboratories Basic Information
Table 96. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 97. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Abbott Laboratories Business Overview
Table 99. Abbott Laboratories Recent Developments
Table 100. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2026-2035) & (K MT)
Table 101. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region (2026-2035) & (M USD)
Table 102. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2026-2035) & (K MT)
Table 103. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2026-2035) & (M USD)
Table 104. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2026-2035) & (K MT)
Table 105. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2026-2035) & (M USD)
Table 106. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2026-2035) & (K MT)
Table 107. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region (2026-2035) & (M USD)
Table 108. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2026-2035) & (K MT)
Table 109. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2026-2035) & (M USD)
Table 110. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2026-2035) & (Units)
Table 111. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2026-2035) & (M USD)
Table 112. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Type (2026-2035) & (K MT)
Table 113. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Type (2026-2035) & (M USD)
Table 114. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price Forecast by Type (2026-2035) & (USD/KG)
Table 115. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) Forecast by Application (2026-2035)
Table 116. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Type (M USD)
Table 4. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Application
Table 5. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Comparison by Region (M USD)
Table 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon-like peptide 1 (GLP-1)-based Therapies as of 2025)
Table 11. Global Market Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (K MT)
Table 27. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Type (M USD)
Table 28. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) by Type (2020-2025)
Table 29. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2020-2025)
Table 30. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) by Type (2020-2025)
Table 31. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Type (2020-2025)
Table 32. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price (USD/KG) by Type (2020-2025)
Table 33. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) by Application
Table 34. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Application
Table 35. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2020-2025) & (K MT)
Table 36. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2020-2025)
Table 37. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Application (2020-2025) & (M USD)
Table 38. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application (2020-2025)
Table 39. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate by Application (2020-2025)
Table 40. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2020-2025) & (K MT)
Table 41. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2020-2025)
Table 42. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region (2020-2025) & (M USD)
Table 43. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region (2020-2025)
Table 44. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2020-2025) & (K MT)
Table 45. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2020-2025) & (K MT)
Table 47. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region (2020-2025) & (M USD)
Table 50. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2020-2025) & (K MT)
Table 51. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region (2020-2025) & (M USD)
Table 54. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT) by Region(2020-2025)
Table 55. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2020-2025)
Table 57. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Novo Nordisk Basic Information
Table 63. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 64. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Novo Nordisk Business Overview
Table 66. Novo Nordisk SWOT Analysis
Table 67. Novo Nordisk Recent Developments
Table 68. AstraZeneca Basic Information
Table 69. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 70. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. AstraZeneca Business Overview
Table 72. AstraZeneca SWOT Analysis
Table 73. AstraZeneca Recent Developments
Table 74. Eli Lily Basic Information
Table 75. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 76. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Eli Lily Business Overview
Table 78. Eli Lily SWOT Analysis
Table 79. Eli Lily Recent Developments
Table 80. GSK Basic Information
Table 81. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 82. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. GSK Business Overview
Table 84. GSK Recent Developments
Table 85. Sanofi Basic Information
Table 86. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 87. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Sanofi Business Overview
Table 89. Sanofi Recent Developments
Table 90. Bristol-Myers Squibb Basic Information
Table 91. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 92. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Bristol-Myers Squibb Business Overview
Table 94. Bristol-Myers Squibb Recent Developments
Table 95. Abbott Laboratories Basic Information
Table 96. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product Overview
Table 97. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Abbott Laboratories Business Overview
Table 99. Abbott Laboratories Recent Developments
Table 100. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2026-2035) & (K MT)
Table 101. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region (2026-2035) & (M USD)
Table 102. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2026-2035) & (K MT)
Table 103. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2026-2035) & (M USD)
Table 104. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2026-2035) & (K MT)
Table 105. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2026-2035) & (M USD)
Table 106. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2026-2035) & (K MT)
Table 107. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region (2026-2035) & (M USD)
Table 108. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2026-2035) & (K MT)
Table 109. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2026-2035) & (M USD)
Table 110. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2026-2035) & (Units)
Table 111. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Country (2026-2035) & (M USD)
Table 112. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Type (2026-2035) & (K MT)
Table 113. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Type (2026-2035) & (M USD)
Table 114. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price Forecast by Type (2026-2035) & (USD/KG)
Table 115. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) Forecast by Application (2026-2035)
Table 116. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Glucagon-like peptide 1 (GLP-1)-based Therapies
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD), 2025-2035
Figure 5. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) (2020-2035)
Figure 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Product Life Cycle
Figure 13. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Manufacturers in 2025
Figure 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers in 2025
Figure 15. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue in 2025
Figure 18. Industry Chain Map of Glucagon-like peptide 1 (GLP-1)-based Therapies
Figure 19. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market PEST Analysis
Figure 20. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Type
Figure 27. Sales Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2020-2025)
Figure 28. Sales Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type in 2025
Figure 29. Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2020-2025)
Figure 30. Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application
Figure 33. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2020-2025)
Figure 34. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application in 2025
Figure 35. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application (2020-2025)
Figure 36. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application in 2025
Figure 37. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate by Application (2020-2025)
Figure 38. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2020-2025)
Figure 39. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region (2020-2025)
Figure 40. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2024
Figure 43. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country in 2024
Figure 45. U.S. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2024
Figure 53. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country in 2024
Figure 55. Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region in 2024
Figure 67. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region in 2024
Figure 68. China Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (K MT)
Figure 79. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2024
Figure 80. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (M USD)
Figure 81. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country in 2024
Figure 82. Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region in 2024
Figure 92. Saudi Arabia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production Market Share by Region (2020-2025)
Figure 103. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT) Growth Rate (2020-2025)
Figure 106. China Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share Forecast by Type (2026-2035)
Figure 111. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Application (2026-2035)
Figure 112. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of Glucagon-like peptide 1 (GLP-1)-based Therapies
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD), 2025-2035
Figure 5. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) (2020-2035)
Figure 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Product Life Cycle
Figure 13. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Manufacturers in 2025
Figure 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers in 2025
Figure 15. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue in 2025
Figure 18. Industry Chain Map of Glucagon-like peptide 1 (GLP-1)-based Therapies
Figure 19. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market PEST Analysis
Figure 20. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Type
Figure 27. Sales Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2020-2025)
Figure 28. Sales Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type in 2025
Figure 29. Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type (2020-2025)
Figure 30. Market Share of Glucagon-like peptide 1 (GLP-1)-based Therapies by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application
Figure 33. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2020-2025)
Figure 34. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application in 2025
Figure 35. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application (2020-2025)
Figure 36. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application in 2025
Figure 37. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate by Application (2020-2025)
Figure 38. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2020-2025)
Figure 39. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region (2020-2025)
Figure 40. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2024
Figure 43. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country in 2024
Figure 45. U.S. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2024
Figure 53. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country in 2024
Figure 55. Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region in 2024
Figure 67. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region in 2024
Figure 68. China Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (K MT)
Figure 79. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2024
Figure 80. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (M USD)
Figure 81. South America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country in 2024
Figure 82. Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region in 2024
Figure 92. Saudi Arabia Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Production Market Share by Region (2020-2025)
Figure 103. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT) Growth Rate (2020-2025)
Figure 106. China Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share Forecast by Type (2026-2035)
Figure 111. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Application (2026-2035)
Figure 112. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share Forecast by Application (2026-2035)
